Abstract:Enterohemorrhagic Escherichia coli (EHEC) is a subset of pathogenic E. coli that can cause diarrhea or hemorrhagic colitis in humans. Hemorrhagic colitis occasionally progresses to hemolytic uremic syndrome (HUS), an important cause of acute renal failure in children and morbidity and mortality in adults. Enterohemorrhagic E. coli O157:H7 (EHEC O157:H7) has been known to cause these syndromes since the 1980s, but clinical cases and outbreaks caused by members of other EHEC serogroups are increasingly recognized. In some areas, non-O157 EHEC may account for a greater number of cases than EHEC O157:H7. In 2011, an unusual enteroaggregative E. coli (EAEC) with the serotype O104:H4 was responsible for a severe outbreak of hemorrhagic colitis and HUS in Europe. What all of the HUSassociated E. coli seem to have in common is the ability to produce verotoxins, together with the ability to bind to and colonize human intestines. Because verotoxin genes can be transmitted between bacteria, additional E. coli pathotypes associated with HUS could also be discovered. Ruminants, particularly cattle and sheep, seem to be the maintenance hosts for EHEC O157:H7 and many other verotoxin-producing E. coli. Some, but not all, individual animals carry these organisms in the intestinal tract, and shed them in the feces. Members of other animal species are also infected occasionally. Most infected animals do not develop any clinical signs, although members of some non-O157 serogroups may cause enteric disease in young animals, and EHEC O153 has been linked to a disease that resembles HUS in rabbits. Humans acquire EHEC by direct contact with animal carriers, their feces, infected people, and contaminated soil or water, or via the ingestion of underdone meat, other animal products, contaminated vegetables and fruit, and other foods. The infectious dose for people is very low, which increases the risk of disease. Animals do not seem to be reservoirs for enteroaggregative, verotoxin-producing E. coli, which are probably maintained in humans, but can also be acquired in food.

Commentary: Campylobacter and Hemolytic Uremic Syndrome

Hemolytic Uremic Syndrome Associated With Non-Shigatoxin-producing Infectious Agents: Expanding the Shigatoxin Theory

Enterohemorrhagic Escherichia coli and Other E . coli Causing Hemolytic Uremic Syndrome

Hemolysin from Shiga Toxin-Negative Escherichia Coli O26 Strains Injures Microvascular Endothelium

Diagnosis and Treatment for Shiga Toxin-Producing Escherichia coli Associated Hemolytic Uremic Syndrome

Shiga toxin-producing Escherichia coli infection as a precipitating factor for atypical hemolytic-uremic syndrome

O80:H2-Associated Hemolytic Uremic Syndrome without Hemorrhagic Colitis: A Case Report

An Unusual Case of Clostridium Difficile Colitis and Hemolytic Uremic Syndrome in a Teenager

Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review

Prevalence, Virulence Profiles, and Clinical Significance of Shiga Toxin-Negative Variants of Enterohemorrhagic Escherichia Coli O157 Infection in Humans

Escherichia coli O157: H7: Overview of Clinical and Epidemiological Issues

Seizure as First Manifestation of Hemolytic Uremic Syndrome with Bacteremia due to Shiga Toxin-Producing Escherichia coli

Gastrointestinal involvement in STEC-associated hemolytic uremic syndrome: 10 years in a pediatric center

Pearls & Oy-sters: Neurologic Involvement in Shiga Toxin-Associated Hemolytic Uremic Syndrome

Enterohemorrhagic Escherichia coli Infections and the Hemolytic-Uremic Syndrome

Enterohemorrhagic (Shiga Toxin-Producing) Escherichia coli

[A case of hemolytic uremic syndrome documented co-infection of vertoxin producing Escherichia coli O157 and other pathogens]

Disease severity of Shiga toxin-producing E. coli O157 and factors influencing the development of typical haemolytic uraemic syndrome: a retrospective cohort study, 2009–2012

Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation

Shiga toxin in enterohemorrhagic E.coli: regulation and novel anti-virulence strategies

Comparative genomics to delineate pathogenic potential in non-O157 Shiga toxin-producing Escherichia coli (STEC) from patients with and without haemolytic uremic syndrome (HUS) in Norway